Frontal Dopamine D 2/3 Receptor Binding in Drug-Naive First-Episode Schizophrenic Patients Correlates with Positive Psychotic Symptoms and Gender

Biological Psychiatry

Volumn 60, Issue 6, 2006, Pages 621-629

  Glenthoj, Birte Y ^a   Mackeprang, Torben ^a   Svarer, Claus ^a   Rasmussen, Hans ^a   Pinborg, Lars H ^a   Friberg, Lars ^a   Baaré, William ^a   Hemmingsen, Ralf ^a   Videbaek, Charlotte ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

drug naive; epidepride; extrastriatal dopamine D 2 receptor; Schizophrenia; sex differences; single tomography

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; EPIDEPRIDE I 123; RADIOLIGAND; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HEMISPHERE; HUMAN; MALE; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHOSIS; RECEPTOR BINDING; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL SIGNIFICANCE; THALAMUS;

ADULT; BENZAMIDES; BRAIN MAPPING; BRIEF PSYCHIATRIC RATING SCALE; CASE-CONTROL STUDIES; CONTRAST MEDIA; FEMALE; FRONTAL LOBE; HUMANS; IODINE ISOTOPES; MALE; PYRROLIDINES; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEX CHARACTERISTICS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 33748741284     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2006.01.010     Document Type: Article

References (60)

1. Abi-Dargham A., Mawlawi O., Lombardo I., Gil R., Martinez D., Huang Y., et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 22 (2002) 3708-3719
2. Abi-Dargham A., Rodenhiser J., Printz D., Zea-Ponce Y., Gil R., Kegeles L.S., et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A 97 (2000) 8104-8109
3. Ashburner J., and Friston K. Multimodal image coregistration and partitioning-a unified framework. Neuroimage 6 (1997) 209-217
4. Bast T., Pezze M.A., and Feldon J. Dopamine receptor blockade in the rat medial prefrontal cortex reduces spontaneous and amphetamine-induced activity and does not affect prepulse inhibition. Behav Pharmacol 13 (2002) 669-673
5. Bergstrom K.A., Halldin C., Kuikka J.T., Swahn C.G., Tiihonen J., Hiltunen J., et al. The metabolite pattern of [123I]beta-CIT determined with a gradient HPLC method. Nucl Med Biol 22 (1995) 971-976
6. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., de B.A., et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 94 (1997) 2569-2574
7. Buchsbaum M.S., Someya T., Teng C.Y., Abel L., Chin S., Najafi A., et al. PET and MRI of the thalamus in never-medicated patients with schizophrenia. Am J Psychiatry 153 (1996) 191-199
8. Byne W., Buchsbaum M.S., Mattiace L.A., Hazlett E.A., Kemether E., Elhakem S.L., et al. Postmortem assessment of thalamic nuclear volumes in subjects with schizophrenia. Am J Psychiatry 159 (2002) 59-65
9. Cutting J. The role of right hemisphere dysfunction in psychiatric disorders. Br J Psychiatry 160 (1992) 583-588
10. Ellenbroek B.A., Budde S., and Cools A.R. Prepulse inhibition and latent inhibition: the role of dopamine in the medial prefrontal cortex. Neuroscience 75 (1996) 535-542
11. Fagerlund B., Mackeprang T., Gade A., and Glenthoj B.Y. Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in first-episode drug-naive schizophrenic patients. CNS Spectr 9 (2004) 364-374
12. Farde L., Wiesel F.A., Jansson P., Uppfeldt G., Wahlen A., and Sedvall G. An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET. Psychopharmacology (Berl) 94 (1988) 1-7
13. Fibiger H.C. Neuroanatomical targets of neuroleptic drugs as revealed by Fos immunochemistry. J Clin Psychiatry 55 Suppl B (1994) 33-36
14. Glenthoj B., Mogensen J., Laursen H., Holm S., and Hemmingsen R. Electrical sensitization of the meso-limbic dopaminergic system in rats: a pathogenetic model for schizophrenia. Brain Res 619 (1993) 39-54
15. Glenthoj B.Y., and Hemmingsen R. Transmitter dysfunction during the process of schizophrenia. Acta Psychiatr Scand Suppl 395 (1999) 105-112
16. Glenthoj B.Y., Mogensen J., Laursen H., and Hemmingsen R. Dopaminergic sensitization of rats with and without early prefrontal lesions: implications for the pathogenesis of schizophrenia. Int J Neuropsychopharmcol 2 (1999) 271-281
17. Goldman-Rakic P.S., Castner S.A., Svensson T.H., Siever L.J., and Williams G.V. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl) 174 (2004) 3-16
18. Goldman-Rakic P.S., and Selemon L.D. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr Bull 23 (1997) 437-458
19. Grace A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41 (1991) 1-24
20. Gurevich E.V., and Joyce J.N. Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology 20 (1999) 60-80
21. Hafner H., Riecher-Rossler A., an der H.W., Maurer K., Fatkenheuer B., and Loffler W. Generating and testing a causal explanation of the gender difference in age at first onset of schizophrenia. Psychol Med 23 (1993) 925-940
22. Hall H., Farde L., Halldin C., Hurd Y.L., Pauli S., and Sedvall G. Autoradiographic localization of extrastriatal D2-dopamine receptors in the human brain using [125I]epidepride. Synapse 23 (1996) 115-123
23. Hallonquist J.D., Seeman M.V., Lang M., and Rector N.A. Variation in symptom severity over the menstrual cycle of schizophrenics. Biol Psychiatry 33 (1993) 207-209
24. Heinz A., Romero B., Gallinat J., Juckel G., and Weinberger D.R. Molecular brain imaging and the neurobiology and genetics of schizophrenia. Pharmacopsychiatry 36 Suppl 3 (2003) S152-S157
25. Kaasinen V., Nagren K., Hietala J., Farde L., and Rinne J.O. Sex differences in extrastriatal dopamine d(2)-like receptors in the human brain. Am J Psychiatry 158 (2001) 308-311
26. Kaasinen V., Nurmi E., Bruck A., Eskola O., Bergman J., Solin O., et al. Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex. Brain 124 (2001) 1125-1130
27. Karlsson P., Farde L., Halldin C., and Sedvall G. PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am J Psychiatry 159 (2002) 761-767
28. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13 (1987) 261-276
29. Kessler R.M., Ansari M.S., de P.T., Schmidt D.E., Clanton J.A., Smith H.E., et al. High affinity dopamine D2 receptor radioligands. 1. Regional rat brain distribution of iodinated benzamides. J Nucl Med 32 (1991) 1593-1600
30. Kessler R.M., Ansari M.S., Schmidt D.E., de P.T., Clanton J.A., Innis R., et al. High affinity dopamine D2 receptor radioligands. 2. [125I]epidepride, a potent and specific radioligand for the characterization of striatal and extrastriatal dopamine D2 receptors. Life Sci 49 (1991) 617-628
31. Kessler R.M., Votaw J.R., Schmidt D.E., Ansari M.S., Holdeman K.P., de P.T., et al. High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. Life Sci 53 (1993) 241-250
32. Kuikka J.T., Akerman K.K., Hiltunen J., Bergstrom K.A., Rasanen P., Vanninen E., et al. Striatal and extrastriatal imaging of dopamine D2 receptors in the living human brain with [123I]epidepride single-photon emission tomography. Eur J Nucl Med 24 (1997) 483-487
33. Kuikka J.T., Repo E., Bergstrom K.A., Tupala E., and Tiihonen J. Specific binding and laterality of human extrastriatal dopamine D2/D3 receptors in late onset type 1 alcoholic patients. Neurosci Lett 292 (2000) 57-59
34. Lacroix L., Broersen L.M., Feldon J., and Weiner I. Effects of local infusions of dopaminergic drugs into the medial prefrontal cortex of rats on latent inhibition, prepulse inhibition and amphetamine induced activity. Behav Brain Res 107 (2000) 111-121
35. Laruelle M. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Nucl Med 42 (1998) 211-221
36. Laruelle M. The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res Brain Res Rev 31 (2000) 371-384
37. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A 93 (1996) 9235-9240
38. Lassen N.A. Neuroreceptor quantitation in vivo by the steady-state principle using constant infusion or bolus injection of radioactive tracers. J Cereb Blood Flow Metab 12 (1992) 709-716
39. Lohr J.B., and Caligiuri M.P. Lateralized hemispheric dysfunction in the major psychotic disorders: historical perspectives and findings from a study of motor asymmetry in older patients. Schizophr Res 27 (1997) 191-198
40. Mackeprang T., Kristiansen K.T., and Glenthoj B.Y. Effects of antipsychotics on prepulse inhibition of the startle response in drug-naive schizophrenic patients. Biol Psychiatry 52 (2002) 863-873
41. Paspalas C.D., and Goldman-Rakic P.S. Presynaptic D1 dopamine receptors in primate prefrontal cortex: target-specific expression in the glutamatergic synapse. J Neurosci 25 (2005) 1260-1267
42. Persaud R., and Cutting J. Lateralized anomalous perceptual experiences in schizophrenia. Psychopathology 24 (1991) 365-368
43. Pietrzyk U., Herholz K., Fink G., Jacobs A., Mielke R., Slansky I., et al. An interactive technique for three-dimensional image registration: validation for PET, SPECT, MRI and CT brain studies. J Nucl Med 35 (1994) 2011-2018
44. Pinborg L.H., Videbaek C., Knudsen G.M., Swahn C.G., Halldin C., Friberg L., et al. Dopamine D(2) receptor quantification in extrastriatal brain regions using [(123)I]epidepride with bolus/infusion. Synapse 36 (2000) 322-329
45. Seamans J.K., and Yang C.R. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 74 (2004) 1-58
46. Seeman P., Lee T., Chau-Wong M., and Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261 (1976) 717-719
47. Skarsfeldt T. Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Eur J Pharmacol 281 (1995) 289-294
48. Suhara T., Okubo Y., Yasuno F., Sudo Y., Inoue M., Ichimiya T., et al. Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch Gen Psychiatry 59 (2002) 25-30
49. Swerdlow N.R., Pitcher L., Noh H.R., and Shoemaker J.M. Startle gating in rats is disrupted by chemical inactivation but not D2 stimulation of the dorsomedial thalamus. Brain Res 953 (2002) 246-254
50. Talvik M., Nordstrom A.L., Olsson H., Halldin C., and Farde L. Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [11C]FLB 457. Int J Neuropsychopharmacol 6 (2003) 361-370
51. Tuppurainen H., Kuikka J., Viinamaki H., Husso-Saastamoinen M., Bergstrom K., and Tiihonen J. Extrastriatal dopamine D 2/3 receptor density and distribution in drug-naive schizophrenic patients. Mol Psychiatry 8 (2003) 453-455
52. Van Laere K., Koole M., Versijpt J., and Dierckx R. Nonuniform versus uniform attenuation correction in brain perfusion SPET of healthy volunteers. Eur J Nucl Med 28 (2001) 90-98
53. Wang M., Vijayraghavan S., and Goldman-Rakic P.S. Selective D2 receptor actions on the functional circuitry of working memory. Science 303 (2004) 853-856
54. Wang Y., and Goldman-Rakic P.S. D2 receptor regulation of synaptic burst firing in prefrontal cortical pyramidal neurons. Proc Natl Acad Sci U S A 101 (2004) 5093-5098
55. Weinberger D.R., Berman K.F., and Illowsky B.P. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism. Arch Gen Psychiatry 45 (1988) 609-615
56. Willendrup P., Pinborg L.H., Hasselbalch S.G., Adams K.H., Stahr K., Knudsen G.M., et al. Assessment of the precision in co-registration of structural MR-images and PET-images with localized binding. Int Congress Series 1265 (2004) 275-280
57. Winterer G., and Weinberger D.R. Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends Neurosci 27 (2004) 683-690
58. Woods R.P., Mazziotta J.C., and Cherry S.R. MRI-PET registration with automated algorithm. J Comput Assist Tomogr 17 (1993) 536-546
59. Yasuno F., Suhara T., Okubo Y., Sudo Y., Inoue M., Ichimiya T., et al. Low dopamine d(2) receptor binding in subregions of the thalamus in schizophrenia. Am J Psychiatry 161 (2004) 1016-1022
60. Zavitsanou K., Cranney J., and Richardson R. Dopamine antagonists in the orbital prefrontal cortex reduce prepulse inhibition of the acoustic startle reflex in the rat. Pharmacol Biochem Behav 63 (1999) 55-61